"From Lab to Life: Windlas Biotech's Dedication to Health and Wellness"


Windlas family has been in business since 2001. Our journey has been exciting and rewarding with a successful track record of different products, customers and teams.

Windlas Biotech has become one of India’s leading Generic Formulations CDMO manufacturers in a short span. We have done this with our commitment to all the stakeholders, from clients to investors. This pushes us to deliver not only high-quality products but also great profitability. Cruising along the same path, we have also had a significant impact with our Trade Generics & Institutional Business vertical, which is growing at a steady pace. With tremendous potential, this vertical will set the ground for future growth. Riding on the pillars of Scalability, Durability and Profitability, Windlas Biotech is all set to make a deep dent in the industry following our successful IPO and complete fund utilization from the same.


Plant 1 established and production started.


Set up of own brand (Marketing Division)


Ventured into the Markets. Crossed Rs 100 Cr revenue by Windlas Healthcare plant


Plant 2 set up comissioned and crossed Rs. 200 Cr. 1st USFDA inspection cleared for Windlas Healthcare plant


Received private equity investment from Tano Capital


Crossed Rs. 300 Cr. turnover.


Plant 3 set up completed. Launched 1st product in US from WHC


Buyback of Zydus’ share in Windlas Healthcare


Buyback of Zydus’ share in Windlas Healthcare